What Does the Evidence Say About Tysabri and PML Risk?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Legacy Context: From General Health Science to Specific Risk

If you or someone you know is taking Tysabri, concerns about progressive multifocal leukoencephalopathy (PML) are understandable. The link between this medication and the rare brain infection is well-documented, but what does the long-term evidence actually show? This page reviews the scientific data on PML risk, monitoring strategies, and prognosis for patients.

Bridge: Tysabri's Mechanism and PML Risk

Tysabri (natalizumab) is a monoclonal antibody used as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. The drug's prescribing information contains a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, but Tysabri-treated patients have developed this condition even without other immunosuppressive conditions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML includes progressive neurological deficits such as weakness, cognitive changes, visual disturbances, and coordination problems. Diagnosis is confirmed through brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid. The disease often leads to severe disability or death, as noted in the drug's warnings (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Risk Factors and Mechanistic Pathway

Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML compared to those who are antibody negative (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The duration of therapy is a critical factor, with risk increasing after two years of continuous treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Prior use of immunosuppressants, such as other disease-modifying therapies for multiple sclerosis or Crohn's disease, further elevates the risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri blocks the adhesion of immune cells to endothelial cells, preventing their migration into the central nervous system. This reduces immune surveillance in the brain, allowing latent JCV to reactivate and cause PML. The drug's immunosuppressive effect on the central nervous system is the primary mechanism for increased PML risk.

Clinical Evidence and Causation

In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 patients with multiple sclerosis treated for a median of 120 weeks; these patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of 1043 patients with Crohn's disease evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases demonstrate that PML can occur within the first year of treatment, though risk increases with longer exposure. The adequacy of warnings regarding Tysabri and PML is addressed through the boxed warning and the TOUCH Prescribing Program, a restricted distribution program that requires prescribers, patients, and pharmacies to enroll and follow specific monitoring protocols (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri dosing immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information emphasizes that the expected benefit of Tysabri should be sufficient to offset the risk of PML when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For affected patients, causation considerations involve evaluating the presence of risk factors, duration of Tysabri exposure, and the timeline between treatment initiation and PML diagnosis. The drug's labeling explicitly states that Tysabri increases the risk of PML, establishing a causal relationship (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The timeline between exposure and documented harm can vary, with cases reported as early as eight doses and after longer treatment durations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who develop PML while on Tysabri should have their treatment discontinued immediately, and management focuses on supportive care and immune reconstitution. In summary, the evidence demonstrates a clear causal link between Tysabri and PML, with well-defined risk factors and a mechanistic basis. The drug's labeling provides adequate warnings and monitoring recommendations, though the risk remains significant for patients with identified risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the causal relationship between Tysabri and PML?

Tysabri increases the risk of PML, as stated in its boxed warning. The drug's labeling explicitly establishes a causal relationship, with risk factors including anti-JCV antibodies, treatment duration beyond two years, and prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How does Tysabri cause PML?

Tysabri blocks immune cell migration into the central nervous system, reducing immune surveillance and allowing latent JC virus to reactivate, leading to PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the symptoms of PML in Tysabri-treated patients?

Symptoms include progressive neurological deficits such as weakness, cognitive changes, visual disturbances, and coordination problems. Diagnosis is confirmed by brain MRI and JCV DNA detection in CSF (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Tysabri Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.